|Manufacturer:||Valeant Pharmaceuticals International|
Both components of Limbitrol exert their action in the central nervous system.
Extensive studies with chlordiazepoxide in many animal species suggest action in the limbic system.
Recent evidence indicates that the limbic system is involved in emotional response.
Taming action was observed in some species.
The mechanism of action of amitriptyline in man is not known, but the drug appears to interfere with the reuptake of norepinephrine into adrenergic nerve endings.This action may prolong the sympathetic activity of biogenic amines.
Limbitrol is contraindicated in patients with hypersensitivity to either benzodiazepines or tricyclic antidepressants.
It should not be given concomitantly with a monoamine oxidase inhibitor.
Hyperpyretic crises, severe convulsions and deaths have occurred in patients receiving a tricyclic antidepressant and a monoamine oxidase inhibitor simultaneously.
When it is desired to replace a monoamine oxidase inhibitor with Limbitrol, a minimum of 14 days should be allowed to elapse after the former is discontinued.Limbitrol should then be initiated cautiously with gradual increase in dosage until optimum response is achieved.This drug is contraindicated during the acute recovery phase following myocardial infarction.
Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.
There has been a long-standing concern that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients.
Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders.Pooled analyses of short-term placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with MDD, OCD, or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal behavior or thinking (suicidality) during the first few months of treatment in those receiving antidepressants.
The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%.
There was considerable variation in risk among drugs, but a tendency toward an increase for almost all drugs studied.
The risk of suicidality was most consistently observed in the MDD trials, but there were signals of risk arising from some trials in other psychiatric indications (obsessive compulsive disorder and social anxiety disorder) as well.
No suicidesoccurred in any of these trials.
It is unknown whether the suicidality risk in pediatric patients extends to longer-term use, i.e., beyond several months.
It is also unknown whether the suicidality risk extends to adults.All pediatric patients being treated with antidepressants for any indication should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.
Such observation would generally include at least weekly face-to-face contact with patients or their family members or caregivers during the first 4 weeks of treatment, then every other week visits for the next 4 weeks, then at 12 weeks, and as clinically indicated beyond 12 weeks.
Additional contact by telephone may be appropriate between face-to-face visits.Adults with MDD or co-morbid depression in the setting of other psychiatric illness being treated with antidepressants should be observed similarly for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.
Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms.Families and caregivers of pediatric patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers.
Such monitoring should include daily observation by families and caregivers.Prescriptions forChlordiazepoxide and Amitriptyline Hydrochloride Tablets should be written for the smallest quantityof tablets consistent with good patient management, in order to reduce the risk of overdose.Families and caregivers of adults being treated for depression should be similarly advised.